Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The closing price of Merck & Co Inc (NYSE: MRK) was $106.62 for the day, down -0.15% from the previous closing price of $106.78. In other words, the price has decreased by -$0.15 from its previous closing price. On the day, 7.87 million shares were traded. MRK stock price reached its highest trading level at $107.59 during the session, while it also had its lowest trading level at $106.425.
Ratios:
Our analysis of MRK’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 14.50 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 20.28. For the most recent quarter (mrq), Quick Ratio is recorded 1.44 and its Current Ratio is at 1.66. In the meantime, Its Debt-to-Equity ratio is 0.80 whereas as Long-Term Debt/Eq ratio is at 0.77.
On November 24, 2025, Wells Fargo Upgraded its rating to Overweight which previously was Equal Weight but kept the price unchanged to $125.
On November 13, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $105.Scotiabank initiated its Sector Outperform rating on November 13, 2025, with a $105 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 10 ’25 when Downing Cristal N sold 7,085 shares for $87.00 per share. The transaction valued at 616,395 led to the insider holds 0 shares of the business.
CRISTAL DOWNING bought 7,085 shares of MRK for $616,395 on Nov 10 ’25. On Nov 03 ’25, another insider, Williams David Michael, who serves as the EVP,Chief Info&Digital Officer of the company, sold 8,614 shares for $83.59 each. As a result, the insider received 720,040 and left with 24,578 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRK now has a Market Capitalization of 266313662464 and an Enterprise Value of 287850233856. As of this moment, Merck’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.10, and their Forward P/E ratio for the next fiscal year is 12.74. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.27. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.14 while its Price-to-Book (P/B) ratio in mrq is 5.11. Its current Enterprise Value per Revenue stands at 4.481 whereas that against EBITDA is 9.131.
Stock Price History:
The Beta on a monthly basis for MRK is 0.30, which has changed by 0.07338154 over the last 52 weeks, in comparison to a change of 0.17823458 over the same period for the S&P500. Over the past 52 weeks, MRK has reached a high of $107.05, while it has fallen to a 52-week low of $73.31. The 50-Day Moving Average of the stock is 12.16%, while the 200-Day Moving Average is calculated to be 24.72%.
Shares Statistics:
MRK traded an average of 13.88M shares per day over the past three months and 16000840 shares per day over the past ten days. A total of 2.49B shares are outstanding, with a floating share count of 2.48B. Insiders hold about 0.10% of the company’s shares, while institutions hold 79.82% stake in the company. Shares short for MRK as of 1765756800 were 37162304 with a Short Ratio of 2.68, compared to 1763078400 on 27626151. Therefore, it implies a Short% of Shares Outstanding of 37162304 and a Short% of Float of 1.67.
Dividends & Splits
With its trailing 12-month dividend rate of 3.2, MRK has a forward annual dividend rate of 3.28. Against a Trailing Annual Dividend Yield of 0.02996816. The stock’s 5-year Average Dividend Yield is 3.05. The current Payout Ratio is 46.32% for MRK, which recently paid a dividend on 2025-12-15 with an ex-dividend date of 2025-12-15. Stock splits for the company last occurred on 2021-06-03 when the company split stock in a 1048:1000 ratio.
Earnings Estimates
Its stock is currently analyzed by 16.0 different market analysts. The consensus estimate for the next quarter is $1.77, with high estimates of $2.4 and low estimates of -$1.55.
Analysts are recommending an EPS of between $9.12 and $8.9 for the fiscal current year, implying an average EPS of $8.97. EPS for the following year is $8.27, with 20.0 analysts recommending between $10.05 and $5.25.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 15 analysts. It ranges from a high estimate of $16.39B to a low estimate of $16.02B. As of. The current estimate, Merck & Co Inc’s year-ago sales were $15.62BFor the next quarter, 15 analysts are estimating revenue of $15.99B. There is a high estimate of $16.38B for the next quarter, whereas the lowest estimate is $15.44B.
A total of 19 analysts have provided revenue estimates for MRK’s current fiscal year. The highest revenue estimate was $65.12B, while the lowest revenue estimate was $64.3B, resulting in an average revenue estimate of $64.78B. In the same quarter a year ago, actual revenue was $64.17BBased on 19 analysts’ estimates, the company’s revenue will be $68.14B in the next fiscal year. The high estimate is $69.69B and the low estimate is $65.92B.
